Meeting Materials

PD-5
Background Biliary obstruction can arise in patients with unresectable pancreatic cancer (UPC), which leads to delayed initiation of chemotherapy (CTx). Biliary drainage (BD) is essential for these patients, however, re-obstruction could be frequently observed after BD and impair maintenance of CTx…
PD-6
Background FOLFIRINOX (FFX) is a standard first-line treatment in metastatic pancreatic adenocarcinoma (MPA). Because there is no standard second-line treatment after FFX, evaluation of clinical practice shows frequent use of gemcitabine (Gem) alone or in association with nab-paclitaxel (Gem-Nab)…
PD-7
Background Our investigator-initiated randomized trial in patients with chemorefractory metastatic colorectal cancer (mCRC) patients demonstrated improved PFS and OS in patients receiving bevacizumab combined with trifluridine/tipiracil (FTD/TPI) as compared with patients treated with FTD/TPI alone…
PD-8
Background The oral fluoropyrimidine TAS-102 (TAS) and the multi-kinase inhibitor regorafenib (REGO) both show efficacy as single agents in the treatment of refractory metastatic CRC patients (pts). The REMETY trial was conducted to determine a recommended phase II dose (RP2D) of…
PD-9
Background Universal Screening (US) for Lynch Syndrome (LS) in colorectal cancer (CRC) patients through DNA Mismatch Repair deficiency (dMMR) testing is widely endorsed. However, LS is still largely underdiagnosed mainly because of the low adherence to guidelines among oncologists. Genetic…
PD-10
Background The Asia-Pacific colorectal screening (APCS) score was developed in identifying the potential high-risk population of colorectal cancer (CRC). However, the clinical utility of such a risk score has not been fully elucidated. We aimed to evaluate the diagnostic accuracy…
PD-11
Background Patients diagnosed with metastatic gastrointestinal (GI) cancer have variable symptom burden. However, serial symptom assessments are time-consuming and may be challenging to implement in routine clinical practice. We aimed to determine if a single measurement of…
PD-12
Background In 2019, WHO subclassified grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) into neuroendocrine carcinoma (NEC) or tumors (G3 NET). Yet, few data exist on clinical and molecular profiles for G3 NEN. We aimed to compare the clinicopathological and…
Stay in the know.
OncNet Newsletter